Liraglutide ameliorates nonalcoholic fatty liver disease in diabetic mice via the IRS2/PI3K/Akt signaling pathway

Liraglutide ameliorates nonalcoholic fatty liver disease in diabetic mice via the IRS2/PI3K/Akt signaling pathway

Pijian Yang1,*, Yuzhen Liang2,*, Yunchen Luo,2 Zhengming Li,2 Yumei Wen,1 Jing Shen,1 Ruwen Li,1 Hua Zheng,3 Harvest F Gu4,*, Ning Xia1,*1Department of Endocrinology and Metabolism, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, People’s Republic of China; 2De...

Full description

Bibliographic Details
Main Authors:	Yang P, Liang Y, Luo Y, Li Z, Wen Y, Shen J, Li R, Zheng H, Gu HF, Xia N
Format:	Article
Language:	English
Published:	Dove Medical Press 2019-07-01
Series:	Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy
Subjects:	Glucagon like peptide 1 Liraglutide Nonalcoholic fatty liver disease Insulin resistance Insulin signaling
Online Access:	https://www.dovepress.com/liraglutide-ameliorates-nonalcoholic-fatty-liver-disease-in-diabetic-m-peer-reviewed-article-DMSO

Similar Items

Clinical potential of liraglutide in cardiovascular risk reduction in patients with type 2 diabetes: evidence to date
by: Howell R, et al.
Published: (2019-04-01)

Liraglutide in the treatment of heart failure: insight from FIGHT and LIVE
by: Bo Liang, et al.
Published: (2020-07-01)

Short-term monotherapy with Liraglutide for weight management: A case study
by: Feras Almarshad
Published: (2019-01-01)

Obesity and non-alcoholic fatty liver disease personalized approaches to metabolic risks correction
by: K. A. Komshilova, et al.
Published: (2018-04-01)

Gglucagon-like peptide-1 analogue liraglutide (Saxenda®): mechanism of action, efficacy for the treatment of obesity
by: Tatiana I. Romantsova
Published: (2018-04-01)

Liraglutide Improves Non-Alcoholic Fatty Liver Disease In Diabetic Mice By Modulating Inflammatory Signaling Pathways
by: Luo Y, et al.
Published: (2019-12-01)

Prediction of early response to liraglutide therapy in patients with obesity
by: Oksana V. Logvinova, et al.
Published: (2020-06-01)

Short-term effects of liraglutide on visceral fat adiposity, appetite, and food preference: a pilot study of obese Japanese patients with type 2 diabetes
by: Inoue Kana, et al.
Published: (2011-12-01)

GLP 1 Regulated Intestinal Cell’s Insulin Expression and Selfadaptation before the Onset of Type 2 Diabetes
by: Shivani Srivastava, et al.
Published: (2019-06-01)

LIRAGLUTIDE PLEIOTROPIC EFFECT IN CARDIOVASCULAR RISK REDUCTION IN TYPE 2 DIAbETES — A MANDATE FOR CARDIOLOGIST AND INTERNIST
by: S. V. Nedogoda
Published: (2018-05-01)

Liraglutide Ameliorates β-Amyloid Deposits and Secondary Damage in the Ipsilateral Thalamus and Sensory Deficits After Focal Cerebral Infarction in Rats
by: Hui-Li Zhu, et al.
Published: (2018-12-01)

Efficacy and Safety of the New Appetite Suppressant, Liraglutide: A Meta-Analysis of Randomized Controlled Trials
by: Shinje Moon, et al.
Published: (2021-06-01)

Liraglutide for weight management: a critical review of the evidence
by: A. Mehta, et al.
Published: (2017-03-01)

Does Nonalcoholic Pancreatic Steatosis Always Correlate with Nonalcoholic Fatty Liver Disease?
by: Ulasoglu C, et al.
Published: (2021-06-01)

Neuroprotective Effects of Liraglutide for Stroke Model of Rats
by: Kenichiro Sato, et al.
Published: (2013-10-01)

Efficacy of liraglutide 3 mig therapy in obesity and associated diseases
by: K. A. Komshilova, et al.
Published: (2018-03-01)

Nonalcoholic fatty liver disease: cause or consequence of insulin resistance?
by: Ekaterina E. Mishina, et al.
Published: (2017-12-01)

Pathophysiology of Non Alcoholic Fatty Liver Disease
by: Salvatore Petta, et al.
Published: (2016-12-01)

Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) for the management of nonalcoholic fatty liver disease (NAFLD): A systematic review
by: Xiaodan Lv, et al.
Published: (2020-07-01)

Effect of glucagon-like peptide-1 receptor agonists on adipokine level of nonalcoholic fatty liver disease in rats fed high-fat diet
by: Jin Miaomiao, et al.
Published: (2020-07-01)

Effects of liraglutide and empagliflozin added to insulin therapy in patients with type 2 diabetes: A randomized controlled study
by: Hirotatsu Nakaguchi, et al.
Published: (2020-11-01)

Empagliflozin and Liraglutide Differentially Modulate Cardiac Metabolism in Diabetic Cardiomyopathy in Rats
by: Nguyen Ngoc Trang, et al.
Published: (2021-01-01)

Gut microbiota and nonalcoholic fatty liver disease
by: Mariana V. Machado, et al.
Published: (2012-07-01)

Thyroid dysfunction and insulin resistance in patients with nonalcoholic fatty liver disease
by: Maha Assem, et al.
Published: (2018-01-01)

Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes
by: Fujishima Yuya, et al.
Published: (2012-09-01)

Glucagon-like peptide-1 receptor (GLP-1R) signaling ameliorates dysfunctional immunity in COPD patients
by: Huang J, et al.
Published: (2018-10-01)

Liraglutide exerts an anti-inflammatory action in obese patients with type 2 diabetes
by: Savchenko Liudmyla G., et al.
Published: (2019-09-01)

Combination therapies in the management of type 2 diabetes: the use of insulin degludec/liraglutide
by: Minze MG, et al.
Published: (2016-03-01)

Treatment with Glucagon-Like Peptide-1 Analogues — a Breakthrough in Diabetes Mellitus Type 2 Therapy
by: V.L. Orlenko, et al.
Published: (2014-05-01)

New Potential Targets of Glucagon-Like Peptide 1 Receptor Agonists in Pancreatic β-Cells and Hepatocytes
by: Won-Young Lee
Published: (2017-02-01)

The Association of Impaired Lung Function and Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
by: Philip Chuang, et al.
Published: (2019-08-01)

A Diabetic Patient Complicated With Pancreatic Cancer After Using Liraglutide: A Case Report
by: Shengjie Wu, et al.
Published: (2021-01-01)

Essential Phospholipids in the Treatment of Nonalcoholic Fatty Liver Disease
by: Yu.М. Stepanov, et al.
Published: (2015-11-01)

The relationship between resistin and ghrelin levels with fibrosis in nonalcoholic fatty liver disease
by: Ahmet Tarık Eminler, et al.
Published: (2014-01-01)

Combined insulin detemir and liraglutide therapy in type 2 diabetic patients: a base for an alliance
by: Lyudmila Alexandrovna Ruyatkina, et al.
Published: (2017-06-01)

In Tune with the World Trends: Clinical Aspects of Liraglutide Use in Combination with Insulin in Patients with Diabetes Mellitus (Literature Review and Clinical Observations)
by: O.V. Korpacheva-Zinych, et al.
Published: (2016-10-01)

Clinical characteristics and risk factors of nonalcoholic fatty liver disease in children with obesity
by: Luting Peng, et al.
Published: (2021-03-01)

GLP-1 Analogue Liraglutide Attenuates Mutant Huntingtin-Induced Neurotoxicity by Restoration of Neuronal Insulin Signaling
by: Ching-Chi Chang, et al.
Published: (2018-08-01)

The influence of waist circumference on insulin resistance and nonalcoholic fatty liver disease in apparently healthy Korean adults
by: Deok Yun Ju, et al.
Published: (2013-06-01)

Betatrophin Levels Are Related to the Early Histological Findings in Nonalcoholic Fatty Liver Disease
by: Alper Sonmez, et al.
Published: (2021-06-01)

Cannot write session to /tmp/vufind_sessions/sess_j1nung0lf9ba34d1ldak29utm1